- Have we really avoided 14,000 coronavirus deaths?
- AI doctors outperform their fleshy counterparts, but still we don’t trust them
- Cryptozoology: The scientific study of fictional animals
- The parallels between ‘Taxi Driver’ and the incel movement
- After a six-year battle, Malka Leifer may finally be extradited
According to the company tied to a potential COVID vaccine, as much as a billion doses could be developed by the end of 2020.
Anglo-Swedish drugmaker AstraZeneca has announced that it could develop a billion doses of a potential COVID-19 vaccine by September should the initial trials prove successful.
The vaccine is being developed by the University of Oxford, which started human testing in April. Only a handful of the vaccines in development have progressed this far. As it stands around a hundred of these programs exist, with experts believing that an effective method of prevention is about twelve to eighteen months away.
Sir John Bell, the Regius Professor of Medicine at Oxford University, told NBC that the researchers would know if the vaccine is effective by June, but added that the chances of success were “pretty good.”
“Coronavirus doesn’t mutate at the pace of flu as far as we can see but it’s also quite a tricky virus in terms of dictating long-term immune responses to it and as a result, I suspect we may need to have relatively regular vaccinations against coronavirus going into the future. That, of course, remains to be seen,” he said.
Sir John Bell, the Regius Professor of Medicine at Oxford University, told NBC that he’d know if the vaccine is effective by June, but added that the chances of success were “pretty good.”
Pascal Soriot, the chief executive of AstraZeneca, said: “This pandemic is a global tragedy and it is a challenge for all of humanity. We need to defeat the virus together or it will continue to inflict huge personal suffering and leave long-lasting economic and social scars in every country around the world. We are so proud to be collaborating with Oxford University to turn their groundbreaking work into a medicine that can be produced on a global scale.
“We would like to thank the US and UK governments for their substantial support to accelerate the development and production of the vaccine. We will do everything in our power to make this vaccine quickly and widely available.”